For det primære endpoint, DFS, overføres hazard ratio til en absolut gavnlig effekt udtrykt i en 2- års disease- free survival rate på 7, 6 procentpoint (85, 8% versus 78, 2%) til fordel for Herceptin- armen.
For the primary endpoint, DFS, the hazard ratio translates into an absolute benefit, in terms of a 2-year disease-free survival rate, of 7.6 percentage points (85.8% vs 78.2%) in favour of the Herceptin arm.